VARIATIONS OF ADIPOKINE PROFILE IN PATIENTS DIAGNOSED WITH RECTAL CARCINOMA.

adipokines adiponectin leptin rectal carcinoma

Journal

Acta endocrinologica (Bucharest, Romania : 2005)
ISSN: 1841-0987
Titre abrégé: Acta Endocrinol (Buchar)
Pays: Romania
ID NLM: 101269720

Informations de publication

Date de publication:
Historique:
entrez: 4 2 2020
pubmed: 6 2 2020
medline: 6 2 2020
Statut: ppublish

Résumé

Adipokine secretion is influenced by various disease conditions. We wanted to check the impact of rectal carcinoma (RC) on adipokine profile. We evaluated serum leptin and adiponectin levels in 24 RC patients (12 males and 12 females) as well as in the same number of age, sex and weight-matched healthy controls. Adipokines were oppositely correlated with body weight (BW) in controls and RC patients. Women had higher adipokine levels than men. Healthy controls had higher leptin (37.6.±7.8 Adipokine profiles of patients with RC differ from the healthy population, possibly reflecting an adaptation to the disease rather than a triggering factor. These differences may find clinical applications for the prognosis of disease evolution.

Sections du résumé

BACKGROUND BACKGROUND
Adipokine secretion is influenced by various disease conditions.
PURPOSE OBJECTIVE
We wanted to check the impact of rectal carcinoma (RC) on adipokine profile.
PATIENTS AND METHODS METHODS
We evaluated serum leptin and adiponectin levels in 24 RC patients (12 males and 12 females) as well as in the same number of age, sex and weight-matched healthy controls.
RESULTS RESULTS
Adipokines were oppositely correlated with body weight (BW) in controls and RC patients. Women had higher adipokine levels than men. Healthy controls had higher leptin (37.6.±7.8
CONCLUSION CONCLUSIONS
Adipokine profiles of patients with RC differ from the healthy population, possibly reflecting an adaptation to the disease rather than a triggering factor. These differences may find clinical applications for the prognosis of disease evolution.

Identifiants

pubmed: 32010365
doi: 10.4183/aeb.2019.407
pii: aeb.2019.407
pmc: PMC6992412
doi:

Types de publication

Journal Article

Langues

eng

Pagination

407-409

Informations de copyright

©by Acta Endocrinologica Foundation.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Références

Trends Pharmacol Sci. 2015 Jul;36(7):461-70
pubmed: 26022934
Anticancer Res. 2009 Aug;29(8):3321-7
pubmed: 19661351
Peptides. 2018 Sep;107:25-31
pubmed: 30076861
World J Gastroenterol. 2010 Mar 14;16(10):1252-7
pubmed: 20222170
Braz J Med Biol Res. 2013 Mar;46(3):306-10
pubmed: 23558862
Am J Epidemiol. 2017 May 1;185(9):751-764
pubmed: 28387787
Eur J Cancer. 2017 Oct;84:69-80
pubmed: 28787661
Rev Med Chir Soc Med Nat Iasi. 2016 Apr-Jun;120(2):252-7
pubmed: 27483701
Cell Biochem Funct. 2016 Dec;34(8):533-545
pubmed: 27859423
Asian Pac J Cancer Prev. 2014;15(1):397-405
pubmed: 24528064
World J Gastroenterol. 2014 Jun 28;20(24):7941-9
pubmed: 24976730
Acta Endocrinol (Buchar). 2018 Oct-Dec;14(4):491-497
pubmed: 31149302

Auteurs

A Florescu (A)

"Gr. T. Popa" University of Medicine and Pharmacy -, Endocrinology, Iasi, Romania.

S Bilha (S)

"Gr. T. Popa" University of Medicine and Pharmacy -, Endocrinology, Iasi, Romania.

I Grigoras (I)

"Gr. T. Popa" University of Medicine and Pharmacy - Intensive Care, Iasi, Romania.

D Branisteanu (D)

"Gr. T. Popa" University of Medicine and Pharmacy -, Endocrinology, Iasi, Romania.

Classifications MeSH